Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

The instinct to protect and secure a child’s future—especially when it comes to their health—is one of the deepest and most ...

Lisocabtagene maraleucel delivers sustained survival benefits and long-term disease control in relapsed or refractory LBCL.

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today ...